Skip to main content
. 2013 Apr 18;346:f1908. doi: 10.1136/bmj.f1908

Table 1.

 Baseline characteristics of respondents at five year follow-up by randomisation to surgical or medical management for chronic gastro-oesophageal reflux disease. Values are numbers (percentages) of participants unless stated otherwise

Characteristic Surgical (n=127 maximum) Medical (n=119 maximum) P value of difference*
Mean (SD) age in years 48.5 (9.3)
(n=127)
46.4 (11.6)
(n=119)
0.12
Sex:
 Men 79/127 (62) 76/119 (64) 0.79
 Women 48/127 (38) 43/119 (36)
Mean (SD) body mass index 29.0 (4.3)
(n=127)
27.7 (3.8)
(n=119)
0.01
Mean (SD) months of antireflux medication before trial entry 57.2 (63.4)
(n=124)
46.3 (60.1)
(n=117)
0.17
Erosive oesophagitis:
 Yes 63/111 (57) 68/108 (63) 0.35
 No 48/111 (43) 39/108 (36)
H pylori infection status:
 Positive (treated) 6/96 (6) 10/92 (11) 0.52
 Positive (untreated) 1/96 (1) 2/92 (2)
 Negative 55/96 (57) 45/92 (49)
 Uncertain 34/96 (35) 34/92 (37)
Hiatus hernia:
 Yes 73/117 (62) 71/114 (62) 0.99
 No 44/117 (38) 43/114 (38)
Mean (SD) questionnaire scores:
 REFLUX† 65.9 (23.7)
(n=121)
68.6 (24.0)
(n=110)
0.38
 EQ-5D‡ 0.736 (0.223)
(n=122)
0.755 (0.228)
(n=118)
0.51
 SF-36 physical§ 44.8 (10.0)
(n=121)
46.1 (9.1)
(n=114)
0.30
 SF-36 mental§ 46.6 (11.0)
(n=121)
46.5 (11.1)
(n=114)
0.98
Taking any proton pump inhibitor 120/125 (96) 109/118 (92) 0.23
Taking any antireflux drug 124/125 (99) 113/118 (96) 0.11

*Using Student’s t test, χ2 test, or Fischer’s exact test as appropriate.

†REFLUX questionnaire a disease-specific measure of quality of life (score range 0–100).

‡EuroQol EQ-5D measure of health status.

§Short Form (36) Health Survey measure of health status.